Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Models of excellence: improving oncology drug development.

Sharma MR, Maitland ML, Ratain MJ.

Clin Pharmacol Ther. 2012 Nov;92(5):548-50. doi: 10.1038/clpt.2012.99.

2.

Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer.

Claret L, Lu JF, Bruno R, Hsu CP, Hei YJ, Sun YN.

Clin Pharmacol Ther. 2012 Nov;92(5):631-4. doi: 10.1038/clpt.2012.78.

PMID:
22910440
3.

Patterns of practice survey for nonsmall cell lung carcinoma in the U.S.

Choy H, Shyr Y, Cmelak AJ, Mohr PJ, Johnson DH.

Cancer. 2000 Mar 15;88(6):1336-46.

PMID:
10717614
4.

Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.

Chu BF, Karpenko MJ, Liu Z, Aimiuwu J, Villalona-Calero MA, Chan KK, Grever MR, Otterson GA.

Cancer Chemother Pharmacol. 2013 Jan;71(1):115-21. doi: 10.1007/s00280-012-1986-8.

PMID:
23053268
6.
7.

Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.

Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, Witt K, Botkin D.

J Clin Oncol. 2008 Feb 20;26(6):863-9. doi: 10.1200/JCO.2007.13.2720.

PMID:
18281658
9.

Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.

Yanagihara K, Yoshimura K, Niimi M, Yasuda H, Sasaki T, Nishimura T, Ishiguro H, Matsumoto S, Kitano T, Kanai M, Misawa A, Tada H, Teramukai S, Mio T, Fukushima M.

Cancer Chemother Pharmacol. 2010 Oct;66(5):913-8. doi: 10.1007/s00280-009-1239-7.

PMID:
20069422
10.

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH.

J Clin Oncol. 2004 Mar 1;22(5):777-84.

PMID:
14990632
11.

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH.

J Clin Oncol. 2004 Mar 1;22(5):785-94.

PMID:
14990633
12.

Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes.

Chang GC, Ahn MJ, Wright E, Kim HT, Kim JH, Kang JH, Kim SW, Sherman S, Walzer S.

Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:34-40. doi: 10.1111/j.1743-7563.2011.01400.x.

PMID:
21585706
13.

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.

Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W, Richards D, Bruetman D, Anderson T, Chowhan N, Nattam S, Mantravadi P, Johnson C, Breen T, White A, Einhorn L; Hoosier Oncology Group.; US Oncology..

J Clin Oncol. 2008 Dec 10;26(35):5755-60. doi: 10.1200/JCO.2008.17.7840.

PMID:
19001323
14.

Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung.

Schiller JH, Storer B, Dreicer R, Rosenquist D, Frontiera M, Carbone PP.

J Natl Cancer Inst. 1989 Nov 15;81(22):1739-43.

PMID:
2553993
15.

Treatment of advanced non-small cell lung cancer: the Southwest Oncology Group experience.

Livingston RB.

Semin Oncol. 1988 Dec;15(6 Suppl 7):37-41.

PMID:
2851176
16.

Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.

Galetta D, Gebbia V, Giotta F, Durini E, Romito S, Borsellino N, Cazzato C, Pezzella G, Colucci G.

Lung Cancer. 2002 Oct;38(1):79-84.

PMID:
12367797
17.

New chemotherapy combinations with docetaxel in the treatment of patients with non-small cell lung cancer.

Donnellan P, Armstrong J, Rowan S, Fennelly D, Lynch V, McDonnell T, McNicholas W, Crown J.

Semin Oncol. 1998 Jun;25(3 Suppl 8):20-3.

PMID:
9704672
18.

Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.

Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R.

Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310. Review. Erratum in: Health Technol Assess. 2015 May;17(31):281-2.

19.

A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer.

Lee JJ, Han JY, Lee DH, Kim HY, Chun JH, Lee HG, Yoon SM, Lee SY, Lee JS.

Jpn J Clin Oncol. 2006 Dec;36(12):761-7.

20.

A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.

Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, Nakamura Y, Ohmatsu H, Sugawara S, Minato K, Fukuda M, Yokoyama A, Takeuchi M, Michimae H, Gemma A, Kudoh S; Tokyo Cooperative Oncology Group..

Ann Oncol. 2015 Jul;26(7):1401-8. doi: 10.1093/annonc/mdv190.

Items per page

Supplemental Content

Support Center